PROGRAM ABSTRACT The Cancer Biology Training Program (CBTP) at the University of Chicago is a multi-disciplinary program whose core mission is to train graduate students and post-doctoral researchers in different areas of cancer research, including but not limited to fundamental molecular mechanisms in cancer biology, systems approaches, reactivation of developmental programs and use of model organisms, organ site biology, cancer therapeutics and cancer population genetics. In addition, our trainees receive robust grounding in hypothesis building and testing, the ethics of scientific endeavor, teaching skills and an understanding of how their work contributes to human well-being and disease management in society. Over the past 5 years of training grant support, our cancer biology program has firmly established itself as an effective and vibrant training program, training the next generation of cancer biologists needed to meet the health cares challenges arising from increasing cancer incidence in society. Our 43 faculty trainers have maintained an outstanding publication record and have been recognized by many prestigious honors. Despite a challenging funding climate, our faculty have increased direct funding of their research in 2013 compared to 2008. Strong institutional support has also allowed us to recruit talented new faculty whose expertise has increased the research opportunities for our trainees in exciting new areas of cancer biology and science. Significantly, we continue to receive an ever-increasing number of qualified applicants to our program. We are also pleased that we have been able to make significant increases in numbers of under-represented minorities recruited to our program, and these trainees are amongst our most dynamic. We have evaluated our program rigorously over the past 5 years to improve yet further our curriculum to meet the changing face of cancer research in this decade. In particular, we have developed new aspects of the curriculum, with altered demands in formal coursework, as well as introduced advances in personal development opportunities for trainees. The program has also come under new leadership with Dr. Kay Macleod taking over from Dr. Geof Greene as Director of this training grant. As with all previous leadership changes to the program, continuity remains thanks to Dr. Macleod having worked closely with Dr. Greene in the past 5 years and Dr. Greene remaining part of the leadership structure. Importantly, Dr. Macleod brings renewed energy and ideas to keep the program purposeful and goal-oriented in its training objectives. In summary, with our expert body of faculty trainers and talented group of young trainees, plus a constantly improving curriculum and training environment, our program has been highly successful in terms of trainee productivity and career outcomes. Given these strength of our program and our sustained ability to recruit increased numbers of qualified, outstanding trainees, we suggest that the program needs and merits retaining the number of pre-doctoral (8) and post-doctoral (3) slots in this training grant renewal.
The Cancer Biology Training Grant at the University of Chicago trains the next generation of cancer researchers with the scientific skills, knowledge and innovative ideas to tackle the growing challenges of cancer prevention, detection and treatment. This is of particular importance for Public Health as cancer remains one of the deadliest diseases nationwide killing more than half a million people in the United States each year. With an ageing US population due to reduced mortality from other diseases, cancer is likely to further increase in incidence over the coming decades and the demand for highly skilled individuals as part of an expert Biomedical Research Workforce will also increase to meet this growing challenge to Public Health.
|Savage, Peter A; Leventhal, Daniel S; Malchow, Sven (2014) Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol Rev 259:245-58|
|Mason, Jennifer M; Logan, Hillary L; Budke, Brian et al. (2014) The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors. Cancer Res 74:3546-55|
|Isikbay, Masis; Otto, Kristen; Kregel, Steven et al. (2014) Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer 5:72-89|
|Wheeler, Heather E; Aquino-Michaels, Keston; Gamazon, Eric R et al. (2014) Poly-omic prediction of complex traits: OmicKriging. Genet Epidemiol 38:402-15|
|Moen, Erika L; Stark, Amy L; Zhang, Wei et al. (2014) The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol Cancer Ther 13:1334-44|
|Gamazon, Eric R; Lamba, Jatinder K; Pounds, Stanley et al. (2013) Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood 121:4366-76|
|Budke, Brian; Kalin, Jay H; Pawlowski, Michal et al. (2013) An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem 56:254-63|
|Reyes, Edwin E; Kunovac, Stefan K; Duggan, Ryan et al. (2013) Growth kinetics of CD133-positive prostate cancer cells. Prostate 73:724-33|
|Wheeler, Heather E; Maitland, Michael L; Dolan, M Eileen et al. (2013) Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet 14:23-34|
|Budke, Brian; Chan, Yuen-Ling; Bishop, Douglas K et al. (2013) Real-time solution measurement of RAD51- and RecA-mediated strand assimilation without background annealing. Nucleic Acids Res 41:e130|
Showing the most recent 10 out of 57 publications